8月13日 - ** 生物技术公司ImmunityBio IBRX.O股价上涨4.5%，至2.58美元
** 公司称其实验性细胞疗法在一项早期研究中帮助两名患者消除了一种血癌的所有症状
** 这种名为CD19 CAR-NK的疗法正在开发中，用于治疗Waldenstrom巨球蛋白血症--一种影响白细胞的罕见、生长缓慢的癌症。
** 患者对该疗法的耐受性良好，无明显毒副作用 - IBRX
** 其中一名接受 CD19 CAR-NK 与抗体药物利妥昔单抗联合治疗的患者在治疗六个月后病情仍在缓解 - IBRX
** 包括盘中走势在内，股价累计上涨 2.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.